ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0048

Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States

Onengiya Harry1, Carl Langefeld2, Miranda Marion3, Trent Younts3, Lori Crosby4, Mara Vitolins3 and Avani Modi4, 1Wake Forest School of Medicine, Clemmons, NC, 2Wake Forest School of Medicine, Winston Salem, NC, 3Wake Forest School of Medicine, Winston-Salem, 4Cincinnati Children's Hospital Medical Center, Cincinnati

Meeting: ACR Convergence 2020

Keywords: clinical trial, health behaviors, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient and family participation in research is critical to improving health outcomes, and identifying factors that contribute to participation or lack of participation in clinical trials is a necessary first step. There is limited data regarding why patients with lupus choose to participate in clinical trials. Research in other conditions has identified factors including age, race/ethnicity, gender, presence of co-morbidities, and disease severity. The primary objective of this study was to examine whether age, race/ethnicity, sex, or greater disease organ involvement are associated with previous clinical trial participation in patients with lupus.

Methods: Data were collected by The Lupus and Allied Diseases Association, the Lupus Foundation of America, and the Lupus Research Alliance for their Externally-led Patient-Focused Drug Development (PFDD) Initiative. From this dataset, we examined the influence of age, sex, race/ethnicity, and organ involvement on clinical trial participation. Data was available for 2,100 individuals with lupus or their parents/legal guardians for children. Participants completed a 46-question survey (in English or Spanish) electronically or on paper, which was distributed online or at lupus events. Logistic regression was used to test a model including demographic and disease characteristics; it was expanded to include duration of illness, number of medications, number of comorbidities, and number of other autoimmune diseases.

Results: Survey participants’ characteristics are summarized in Table 1. More than 50% of respondents had not participated in a clinical trial. Univariate analysis suggests that race/ethnicity, age of symptom onset, illness duration, lupus type, and history of organ transplant were associated with trial participation. The expanded model indicated that African Americans (OR=1.71) and Hispanics (OR=1.42) were more likely to participate than whites, respondents reporting longer illness duration were more likely to participate (OR=1.52), and respondents with a greater number of medications (OR=1.13) and other self-reported autoimmune diseases (OR=1.07) were more likely to participate in a clinical trial (Table 2).

Conclusion: Several medical (i.e., illness duration, number of medications and comorbid autoimmune disorder) and demographic (i.e., race/ethnicity) factors appear to be important determinants of participation in clinical trials. Compared to previous studies, these data suggest that African American and Hispanic individuals are willing to participate in clinical trials, but perhaps only trials that are related to their chronic condition, or this finding may be due to underrepresentation in this sample. Future research studies with larger samples of diverse participants are recommended.  

Table 1. Demographic and disease characteristics of clinical trial non-participants vs. participants

Table 2. Multivariate logistic regression model showing effect of different variables (e.g., age (on ordinal scale), gender, race) on clinical trial participation


Disclosure: O. Harry, Lupus Research Alliance, 2; C. Langefeld, Lupus Research Alliance, 2; M. Marion, Lupus Research Alliance, 2; T. Younts, None; L. Crosby, Lupus Research Alliance, 2; M. Vitolins, None; A. Modi, Lupus Research Alliance, 2.

To cite this abstract in AMA style:

Harry O, Langefeld C, Marion M, Younts T, Crosby L, Vitolins M, Modi A. Determinants of Participation in Clinical Trials Among Patients with Lupus in the United States [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/determinants-of-participation-in-clinical-trials-among-patients-with-lupus-in-the-united-states/. Accessed June 1, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/determinants-of-participation-in-clinical-trials-among-patients-with-lupus-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences